LSE:AZNPharmaceuticals
AstraZeneca (LSE:AZN) Posts Phase III Survival Win In Small Cell Lung Cancer
AstraZeneca (LSE:AZN) reported that IMFINZI plus Amgen’s tarlatamab improved overall survival in extensive-stage small cell lung cancer in the Phase III DeLLphi-305 trial.
The regimen is described as the first immunotherapy plus bispecific T-cell engager combination to show a survival benefit in this patient group.
The data position IMFINZI as a potential backbone therapy option across different stages of small cell lung cancer, targeting an area of high unmet need.
This kind of oncology...